E Yi Merger with Genor Completed, Taiwan-US Integrated Pharmaceutical Platform Officially Launched

E Yi BioMedicine (1799) and Genor BioPharma (4130) have finalized their merger through a share swap, officially launching an integrated pharmaceutical platform spanning Taiwan and the United States. This strategic integration marks a significant milestone, moving from planning to substantive operations for a platform designed to cover the entire pharmaceutical value chain across both regions.

The core objective of this integration is to construct a comprehensive medical value chain. E Yi BioMedicine, through its US subsidiary Tulex Pharmaceuticals, operates a cGMP-compliant manufacturing facility in New Jersey. This facility has secured 11 US FDA drug approvals, including three 505(b)(2) hybrid new drugs and eight difficult-to-make generic drugs, demonstrating full capabilities from research and development to manufacturing and commercialization.

Genor BioPharma complements this by focusing on local research and development and manufacturing within Taiwan, possessing experience in pharmaceutical development under Asian clinical regulations. It has also served as a Contract Development and Manufacturing Organization (CDMO) for international pharmaceutical companies. The combination connects key segments, research, manufacturing, and market, creating a highly complementary cross-regional industrial structure.

Following the merger, E Yi BioMedicine's chairman, Lin Han-fei, will also assume the chairmanship of Genor BioPharma. Wu Zhi-yong, formerly the general manager of China Chemical, has been appointed as the new general manager of Genor BioPharma. The merged entity plans to further integrate Genor's resources in new drugs, generics, and various dosage forms, expanding its focus on new drugs, challenging generics, and high-technical-barrier preparations. The company also highlighted its US manufacturing base as a competitive advantage, particularly in light of increasing US policies aimed at strengthening domestic pharmaceutical supply chains.